Children (N = 39) | Adults (N = 87) | All (N = 126) | |
---|---|---|---|
All episodes | |||
IV BCAA-free solution treatment duration, days* | |||
N | 30 | 75 | 105 |
Mean (SD) | 4.8 (5.4) | 3.8 (1.4) | 4.1 (3.1) |
Median [min; max] | 3.0 [1.0; 30.0] | 4.0 [1.0; 8.0] | 4.0 [1.0; 30.0] |
Dose (g/kg/day) | |||
N | 26 | 40 | 66 |
Mean (SD) | 1.9 (0.3) | 1.3 (0.5) | 1.5 (0.5) |
Median [min; max] | 2.0 [0.8; 2.0] | 1.1 [0.5; 2.6] | 1.5 [0.5; 2.6] |
Hospitalisation duration, days | |||
N | 39 | 86 | 125 |
Mean (SD) | 7.1 (4.9) | 5.2 (3.0) | 5.8 (3.8) |
Median [min; max] | 6.0 [1.0; 30.0] | 5.0 [2.0; 27.0] | 5.0 [1.0; 30.0] |
N (%) of episodes not treated with HF/HD** | 32 (82.1%) | 86 (98.9) | 118 (93.7%) |
IV BCAA-free solution treatment duration in episodes not treated with HF/HD, days | |||
N | 23 | 74 | 97 |
Mean (SD) | 3.4 (2.0) | 3.8 (1.4) | 3.7 (1.6) |
Median [min; max] | 3.0 [1.0; 8.0] | 4.0 [1.0; 8.0] | 4.0 [1.0; 8.0] |
Hospitalisation duration without HF/HD, days | |||
N | 32 | 85 | 117 |
Mean (SD) | 6.0 (3.1) | 5.2 (3.0) | 5.4 (3.0) |
Median [min; max] | 5.0 [1.0; 13.0] | 5.0 [2.0; 27.0] | 5.0 [1.0; 27.0] |
N (%) of episodes treated with HF/HD** | 7 (17.9%) | 1 (1.1%) | 8 (6.3%) |
Mean (SD) IV BCAA-free solution treatment duration in episodes treated with HF/HD, days** | 9.3 (9.6) | 2.0 (-) | 8.4 (9.3) |
Mean (SD) hospitalisation duration with HF/HD, days | 12.0 (8.3) | 3.0 (-) | 10.9 (8.3) |